At the news
? NEUTRALIMPACT 2/10 144 filed Sep 2, 2026 at 16:10 ET
Director Christopher Kiritsy filed a Form 144 notice of intent to sell 375 shares of Palvella Therapeutics, valued at approximately $58,875, from a stock option exercise. The proposed sale is immaterial relative to the company's $2.2B market cap and represents a routine insider transaction with no meaningful signal.
- Insider: Director Christopher P. Kiritsy
- Proposed sale: 375 shares, estimated value $58,875
- Shares acquired via stock option exercise on the same date
- Sale planned for 09/02/2026 on NASDAQ
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access